Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin and Rituxan for Relapsed/Refractory DLBCL
NCT00073957Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Dec 2003
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Response Rate (Complete and Partial Response) at 12 weeks and Best Overall Response at 12 months. Started Dec 2003; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00073957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073957.